China Health Group Inc. (HKG:8225)

Market Cap	108.49M -33.9%
Revenue (ttm)	31.79M +8.0%
Net Income	-16.65M
EPS	-0.02
Shares Out	995.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Open	0.1090
Previous Close	0.1090
Day's Range	0.1090 - 0.1090
52-Week Range	0.1040 - 0.1980
Beta	-0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About China Health Group

China Health Group Inc., together with its subsidiaries, researches and develops bio, natural, and synthetic drugs in the People’s Republic of China. It engages in the pharmacodynamics and clinical research of drugs; provision of post market and contracted pharmaceutical development services; and technological transfer and services for the research and development of drugs. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in February 2015. China Health Group Inc. was founded in ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1998
• Employees: 32
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 8225

Financial Performance

In 2025, China Health Group's revenue was 28.56 million, an increase of 7.98% compared to the previous year's 26.45 million. Losses were -14.96 million, 3.05% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error